Sarepta Therapeutics (SRPT) Non Operating Income (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Non Operating Income of -$15.3 million for Q1 2026, up 81.64% year-over-year from -$8.4 million in Q1 2025, and down 111.45% quarter-over-quarter from $133.3 million in Q4 2025.
Sarepta Therapeutics (SRPT) Non Operating Income (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Non Operating Income history runs 17 years deep, the most recent figure standing at -$15.3 million for Q1 2026.
- In Q1 2026, Non Operating Income rose 81.64% year-over-year to -$15.3 million; the TTM figure through Mar 2026 stood at $65.4 million (up 239.26% YoY), while the FY2025 annual figure was -$2.4 million, down 105.72% from the prior year.
- Non Operating Income for Q1 2026 stood at -$15.3 million, down from $133.3 million in the prior quarter.
- The five-year high for Non Operating Income was $133.3 million in Q4 2025, with the low at -$374.6 million in Q1 2023.
- The 5-year median for Non Operating Income is -$12.3 million (2023), against an average of -$29.8 million.
- The sharpest annual moves came in 2023 and 2025: Non Operating Income plunged 2069.83% in 2023, then surged 1224.66% in 2025.
- Sarepta Therapeutics' Non Operating Income stood at -$119.9 million in 2022, then jumped by 113.13% to $15.7 million in 2023, then plunged by 36.1% to $10.1 million in 2024, then soared by 1224.66% to $133.3 million in 2025, then slumped by 111.45% to -$15.3 million in 2026.
- Business Quant data shows SRPT's Non Operating Income at -$15.3 million in Q1 2026, $133.3 million in Q4 2025, and -$90.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | -15.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.04 Mn |
| Mar 31, 2026 | -15.26 Mn |
| Dec 31, 2025 | 133.29 Mn |
| Sep 30, 2025 | -90.66 Mn |
| Jun 30, 2025 | 38.06 Mn |
| Mar 31, 2025 | -83.13 Mn |
| Dec 31, 2024 | 10.06 Mn |
| Sep 30, 2024 | 11.81 Mn |
| Jun 30, 2024 | 14.28 Mn |
| Mar 31, 2024 | 6.54 Mn |
| Dec 31, 2023 | 15.75 Mn |
| Sep 30, 2023 | -12.33 Mn |
| Jun 30, 2023 | 118.93 Mn |
| Mar 31, 2023 | -374.62 Mn |
| Dec 31, 2022 | -119.91 Mn |
| Sep 30, 2022 | -125.06 Mn |
| Jun 30, 2022 | -16.96 Mn |
| Mar 31, 2022 | -17.27 Mn |
| Dec 31, 2021 | -16.08 Mn |
| Sep 30, 2021 | -13.45 Mn |